CPhI Worldwide Madrid

Aesica: 'Consolidate your CDMOs into one, easy to manage CDMO!'

By Dan Stanton

- Last updated on GMT

Pharma firms may have over 400 CMOs to manage, says Aesica
Pharma firms may have over 400 CMOs to manage, says Aesica

Related tags Supply chain management Management

Pharma is looking to condense the number of contract manufacturers it works with, says Aesica which has launched a service to help manage its customers’ supply chain.

An ex-GSK exec told delegates at a conference last year​ that pharma firms do not want to be managing hundreds of contractors, but instead want to have around ten partners in their network for reasons of simplicity.

Speaking with Outsourcing-Pharma at the CPhI Worldwide event in Madrid last week, Aesica’s CEO Ian Muir said “large to mid-sized pharma could have anything up to 400 individual suppliers just for product, let alone intermediates,”​ while “small virtual companies with a fairly limited portfolio may have over 100 different touch points with service providers.”

While he agreed that at a macro level pharma is looking to reduce this level, he told us firms are struggling to do this especially where they have a lot of smaller more complex products which one CMO cannot offer.

Therefore, he explained, his firm has launched a service to simplify supply chain management with Aesica itself taking on the management of a pharma customer’s manufacturing partners. While this will not reduce the number of CDMOs, it intends to reduce the burden of dealing with them, he said.

“We consolidate product supply or products for customers from a number of sources​,” Muir said. “Intuitively people say would industry be open to one CDMO working with a number of other CDMOs to provide that consolidation service, but we’re doing it routinely and what it does is give the customer an opportunity to simplify their supply chain.”

According to Muir, there are several models available to customers: “In some situations the contractual relationship remains with the pharma company, so we’re managing the logistics and consolidation, and actually the supply relationship rests with the pharma and the third party; in other cases we actually pick up that relationship.”

And despite having one CDMO managing others, there have been no conflicts of interest or resistance from other outsourcing partners towards Aesica.

“Customers like it as it means there is one less thing that they have to manage,”​ Muir said. “From the other CDMOs I would have thought there would be more barriers but the reality is they treat us like another supplier and so it hasn’t been an issue.

“Because we are working on behalf of a pharma customer in a way there’s almost a warranty behind it, as even though we’re providing the service, they know it is being provided on behalf of someone else.”

Related news

Show more

Related products

show more

Designing an Optimal APAC Clinical Supply Chain

Designing an Optimal APAC Clinical Supply Chain

Catalent | 08-Mar-2023 | Infographic

With clinical study activity increasing across the Asia-Pacific region, it is important for sponsors—both in APAC and globally—to understand the broader...

Plan for success with process liquid and buffer preparation

Plan for success with process liquid and buffer preparation

Thermo Fisher Scientific - Process Liquid Preparation Services | 21-Feb-2023 | Technical / White Paper

Setting the groundwork for successful scale-up is essential for getting a therapeutic to market quickly and efficiently, but navigating the unknowns associated...

Enhance your cGMP chemical supply chain

Enhance your cGMP chemical supply chain

Thermo Fisher Scientific – Production Chemicals and Services | 09-Feb-2023 | Technical / White Paper

Supply chain issues have real, quantifiable impacts on biomanufacturers. However, the right support can make a cGMP supply chain operate seamlessly. Thermo...

Related suppliers

Follow us


View more